XIFIN Inc. Expands its Molecular Diagnostics Industry Expertise

XIFIN Inc., the leading provider of revenue cycle management for diagnostic service providers, announced the addition of Rina Wolf as Vice President of Commercialization Strategies, Consulting & Industry Affairs to the XIFIN team. In this capacity Ms. Wolf will provide consulting services to Molecular Diagnostic Laboratories to assist them in the commercialization of new molecular diagnostic assays and the optimization of their pricing and reimbursement strategies. XIFIN Inc. provides a unique hybrid of outsourced billing services and Software as a Service (SaaS) based billing services to molecular diagnostic laboratories. This unique approach allows Molecular Diagnostic Laboratories to begin by outsourcing their billing and accounts receivables management and then, as they grow, gradually bring their billing in-house without having to change billing platforms or partners.

Ms Wolf is a nationally recognized expert in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry, specializing in Molecular Diagnostic Laboratories. She lectures extensively on these topics and has consulted for major laboratories and laboratory associations throughout the U.S.

Ms. Wolf has demonstrated the ability to develop commercial strategies and policies that are designed to enhance revenue from personalized medicine services. Most recently Ms. Wolf held the position of Vice President of Reimbursement and Regulatory Affairs at Axial Biotech, Inc. where she served on the senior management team that launched ScoliScore™, Axial’s proprietary test for Adolescent Idiopathic Scoliosis prognosis. Ms. Wolf was responsible for creating and implementing their successful reimbursement strategies, including pricing, coding, billing policies and activities and developing patient advocacy programs. ScoliScore is the first molecular diagnostic test developed specifically for the orthopedic community She also continued her role as liaison to the laboratory industry and appropriate regulatory and industry entities. Prior to joining Axial Biotech, Inc. Rina Wolf was the Vice President of Reimbursement and Regulatory Affairs at RedPath Integrated Pathology, Inc., where she was responsible for creating and managing all billing activities and policies; patient advocacy programs; public and private payor coverage/contracting; including obtaining Medicare coverage with value based pricing for RedPath’s PathFinderTG platform, and was the liaison to the appropriate regulatory and industry entities.

Prior to joining RedPath, Ms. Wolf was Director of Reimbursement and Payor Relations for Genomic Health, Inc., the creators of Oncotype DX. At Genomic Health, she helped to develop reimbursement strategies and programs that led to positive coverage policies with major Third Party Payors, as well as a favorable Local Coverage Determination from Genomic Health’s Part B Medicare Carrier, NHIC, and contributed to establishing Oncotype DX as a model for value based pricing for a clinical laboratory test. Her role at Genomic Health also included all contracting activities with payors and clients.

Formerly, Ms. Wolf worked at Esoterix (now LabCorp) as Vice President of Reimbursement and Contracts and was responsible for relationships and contracts with Third Party Payors, Group Purchasing Organizations and key accounts. In addition, Ms. Wolf worked for both Schering Plough and Searle Pharmaceuticals as a hospital and managed care specialty sales representative.

She is a former President and board member of the California Clinical Laboratory Association and is an active participant with the ACLA (American Clinical Laboratory Association) and the Personalized Medicine Coalition. Ms. Wolf has also testified to the Small Business Committee of the U.S. House of Representatives on the impact of CMS billing regulations on Personalized Medicine.

"I am very pleased to have Rina join our team", said Lale White, XIFIN’s CEO and Executive Chairman. "Her expertise is a natural extension of the expert services XIFIN currently provides our clients. Reimbursement strategies, billing, and accounts receivable management are inseparable components in the financial success of a laboratory"

Ms. Wolf has a Bachelor of Arts degree from UCLA and a Masters of HealthCare Administration.

For additional information, Contact: Bill Taylor (858) 436-2995


XIFIN is an innovative software and services company dedicated to optimizing the economics of healthcare. The company’s cloud-based technology and business intelligence platform links healthcare stakeholders in the delivery and reimbursement of care, optimizing both business and patient outcomes and providing informed, streamlined diagnostic and business decision-making. To learn more, visit, or follow XIFIN on Twitter at!/xifin.


Media Relations

To speak with XIFIN directly, contact Fran DuCharme at 858.436.2939 or complete the form below for assistance.

To speak with our PR firm, contact Julie Sculley at 617.986.5730.